• All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasible
  • One-year locoregional control rate was 79%, one-year local progression-free survival (LPFS) was 61%, and one-year overall survival (OS) was 70% in evaluable subjects— achieved at a lower re-irradiation dose than patients’ prior course of radiotherapy
  • Investigators concluded that JNJ-1900 (NBTXR3 may permit clinically meaningful local control using a substantially lower re-irradiation dose than patients’ prior course of radiotherapy
  • Enrollment in the dose-escalation and expansion parts of the study is complete per protocol; following the encourage findings, additional patient enrollment in this study is planned

Data presented at the IASLC 2026 World Conference on Lung Cancer

PARIS and CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updated safety and efficacy data from the completed dose-escalation and expansion phases of a Phase 1 study sponsored by The University of Texas MD Anderson Cancer Center (“UT MD Anderson”) evaluating radiotherapy-activated JNJ-1900 (NBTXR3) for patients with inoperable, locoregionally recurrent non-small cell lung cancer (“NSCLC”) amenable to re-irradiation (“reRT”). The data were presented by study principal investigator Saumil Gandhi, MD, PhD, at the International Association for the Study of Lung Cancer (“IASLC”) 2026 World Conference on Lung Cancer (“WCLC”), taking place September 12–15, 2026 in Seoul, Republic of Korea.

POSTER P2.260: Re-irradiation (ReRT) with NBTXR3 for Inoperable Locoregionally Recurrent Non-Small Cell Lung Cancer (NSCLC): A Phase I Trial

Saumil N. Gandhi, MD, PhD; Enoch Chang, MD; Aileen B. Chen, MD; Stephen G. Chun, MD; Joe Y. Chang, MD, PhD; Steven H. Lin, MD, PhD; Matthew S. Ning, MD, MPH; David Qian, MD; Julianna K. Bronk, MD, PhD; Rahul A. Sheth, MD; Jianjun Zhang, MD, PhD; Tina Cascone, MD, PhD; Marcelo Vailati Negrao, MD; Anne S. Tsao, MD; George R. Blumenschein, MD; Mehmet Altan, MD; John V. Heymach, MD, PhD; James W. Welsh, MD; Suyu Liu, PhD; Zhongxing Liao, MD; Roberto F. Casal, MD — The University of Texas MD Anderson Cancer Center

Patients who are candidates for re-irradiation are frequently limited to palliative radiation doses because of normal-tissue tolerance, and their recurrent tumors typically harbor the most radiation-resistant cells. Effective strategies to safely deliver radiotherapy doses capable of controlling recurrent tumors remain a significant unmet need in this setting.

“Recurrence within a previously irradiated field is one of the least forgiving problems in thoracic oncology,” said Saumil Gandhi, MD, PhD, Department of Thoracic Radiation Oncology, Division of Radiation Oncology at UT MD Anderson. “The normal tissue near the tumor has already received a full course of radiation, so the dose that can delivered safely during a second course is limited. Additionally, the disease that returns is often more radioresistant because it survived radiation the first time. In this study, JNJ-1900 (NBTXR3) was delivered without dose-limiting toxicities, and we observed clinically meaningful local control at a substantially lower re-irradiation dose. These findings warrant evaluation in a randomized trial.”

Results from the pooled dose-escalation and expansion phases showed that all 24 patients completed treatment with JNJ-1900 (NBTXR3) plus re-irradiation with no dose-limiting toxicities. Investigators reported no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3) or to the injection procedure.

Grade 3 radiotherapy-related adverse events occurred in 33% of patients (n=8), and Grade 5 radiotherapy-related adverse events in 8% (n=2). The recommended Phase 2 dose was established at 33% of gross tumor volume.

At a median follow-up of 12 months (data cutoff: August 2026) the one-year locoregional control rate was 79%. One-year local progression-free survival (“LPFS”) was 61% (median 13.6 months), and one-year overall survival (“OS”) was 70% (median 14.8 months). Investigators concluded that JNJ-1900 (NBTXR3) may permit clinically meaningful local control using a substantially lower re-irradiation dose.

“The Nanobiotix team is encouraged by these full-cohort findings in one of the most difficult settings in lung cancer,” said Louis Kayitalire, MD, Chief Medical Officer of Nanobiotix. “If a physics-based approach can improve local control in tissue that has already failed radiation, and do so at a reduced dose, then the conditions in earlier settings, where full-dose radiotherapy reaches previously untreated tissue, could be even more favorable. We look forward to further evaluation in additional patients enrolled to this study and across indications.”

Enrollment in both the dose-escalation and expansion parts of the study is complete per protocol. Following the encouraging findings, additional patient enrollment in this study is planned.

About JNJ-1900 (NBTXR3)

JNJ-1900 (NBTXR3) is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles administered via one-time intratumoral injection and activated by radiotherapy. The product candidate’s mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Proof-of-concept was demonstrated in a randomized Phase 2/3 soft tissue sarcoma study sponsored by Nanobiotix in 2018.

Radiotherapy-activated JNJ-1900 (NBTXR3) is being evaluated across multiple solid tumor indications as a single agent or combination therapy. Given the Company’s focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several Phase 1 and Phase 2 studies evaluating JNJ-1900 (NBTXR3) across tumor types and therapeutic combinations.

In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy.

In 2023, Nanobiotix announced a license agreement for the global development and commercialization of JNJ-1900 (NBTXR3) with Janssen Pharmaceutica NV, a Johnson & Johnson company. Studies being led by Johnson & Johnson include NANORAY-312 (NCT04892173), a global, randomized Phase 3 study in platinum-based chemotherapy-ineligible, locally advanced head and neck squamous cell cancers; LUMIRAY (NCT07219212), a global, phase 1b, open-label study in locally advanced head and neck squamous cell cancers; and CONVERGE (NCT06667908), a phase 2, randomized, open-label, active-controlled study in locally advanced and unresectable Stage III non-small cell lung cancer (NSCLC).

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter

Disclaimer

This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company’s anticipates its financial resources will be adequate to support operations. Words such as “expects”, “intends”, “can”, “could”, “may”, “might”, “plan”, “potential”, “should” and “will” or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company’ management’s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix’s business and financial performance, which include the risk that assumptions underlying the Company’s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on April 2, 2025 under “Item 3.D. Risk Factors”, in Nanobiotix’s 2024 universal registration document filed with the AMF on April 2, 2025 under “chapter 1.5 Risk Factors”, and subsequent filings Nanobiotix makes with the SEC and AMF from time to time, including the Half-Year Report at June 30, 2025 which are available on the SEC’s website at www.sec.gov and on the AMF’s website at www.amf.org, The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.

Nanobiotix
Communications Department
Brandon Owens
VP, Communications
+1 (617) 852-4835
contact@nanobiotix.com
Investor Relations Department
Joanne Choi
VP, Investor Relations (US)
+1 (713) 609-3150
joanne.choi@nanobiotix.com 

Ricky Bhajun
Director, Investor Relations (EU)
+33 (0) 79 97 29 99
investors@nanobiotix.com

Media Relations
France – HARDY
Caroline Hardy
+33 06 70 33 49 50
carolinehardy@outlook.fr

Global – uncapped
Becky Lauer
+1 (646) 286-0057
uncappednanobiotix@uncappedcommunications.com

Attachment

AS Tallinna Sadam’s subsidiary, OÜ TS Shipping, has signed an agreement with Aibel Seatrium Consortium ANS to charter the multifunctional icebreaker MPSV Botnica as an accommodation vessel for the project in the North Sea.

The estimated duration of the charter is 30 days, with options for extension. Charter will start in September 2026.

According to agreement with the Estonian Transport Administration, Botnica provides icebreaking services in Estonian coastal waters from December 20 to April 20.

Tallinna Sadam is one of the largest cargo- and passenger port complexes in the Baltic Sea region. In addition to passenger and freight services, Tallinna Sadam group also operates in shipping business via its subsidiaries – OÜ TS Laevad provides ferry services between the Estonian mainland and the largest islands, and OÜ TS Shipping charters its multifunctional vessel Botnica for icebreaking and offshore services in Estonia and projects abroad. Tallinna Sadam group is also a shareholder of an associate AS Green Marine, which provides waste management services.

Additional information:

Angelika Annus
Head of Investor Relations
Tel. +372 5649 6230
angelika.annus@ts.ee

The share repurchase programme runs as from 5 February 2026 and up to and including 29 January 2027 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 3 billion, cf. Corporate Announcement No. 11/2026 of 5 February 2026. The share repurchase programme is initiated and structured in compliance with the Market Abuse Regulation (Regulation (EU) No 596/2014) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”).

The following transactions have been made under the program:

  Number of
shares
Average purchase
price (DKK)
Transaction
value (DKK)
Accumulated, previous announcement 1,916,299 941.89 1,804,942,913
7 September 2026 10,491 1.101.07 11,551,339
8 September 2026 10,529 1.093.86 11,517,302
9 September 2026 10,954 1.083.08 11,864,007
10 September 2026 10,043 1.092.87 10,975,653
11 September 2026 9,798 1.100.41 10,781,786
Accumulated under the programme 1,968,114 945.90 1,861,633,000

Following settlement of the transactions stated above, Jyske Bank will own a total of 1,968,114 of treasury shares, excluding investments made on behalf of customers and shares held for trading purposes, corresponding to 3.38% of the share capital.

Attached to this corporate announcement, aggregated details on the transactions related to the share repurchase programme are shown by venue.
                                                         
Yours faithfully,
Jyske Bank

Contact: Birger Krøgh Nielsen, CFO, tel. +45 25 26 92 42

Attachment

Sampo plc, stock exchange release, 14 September 2026 at 8:30 am EEST

Sampo plc’s share buybacks week 37/2026

During week 37 (7 September 2026 – 11 September 2026), Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:

Market
(MIC Code)
Daily volume (in number of shares) and weighted average price of the purchased
shares, EUR*
Aggregated weekly volume (in number of shares) and weighted weekly average price of the purchased shares, EUR*
    07/09/2026 08/09/2026 09/09/2026 10/09/2026 11/09/2026 Week 37/2026, total
AQEU Volume 25,371 80,848 81,065 52,551 561 240,396
Average price 9.63 9.53 9.38 9.42 9.45 9.47
CEUX Volume 283,865 283,196 274,328 262,471 119,209 1,223,069
Average price 9.66 9.55 9.45 9.45 9.46 9.52
TQEX Volume 41,668 39,642 38,696 36,347 29,489 185,842
Average price 9.67 9.55 9.47 9.44 9.46 9.53
XHEL Volume 510,062 650,176 646,464 643,590 166,571 2,616,863
Average price 9.65 9.54 9.42 9.45 9.46 9.50
Total, all markets Volume 860,966 1,053,862 1,040,553 994,959 315,830 4,266,170
Average price 9.65 9.54 9.43 9.45 9.46 9.51

* rounded to two decimals

On 6 May 2026, Sampo announced a share buyback programme of up to a maximum of EUR 350 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 7 May 2026, is based on the authorisation granted by Sampo’s Annual General Meeting on 22 April 2026.

After the disclosed transactions, the company owns in total 30,519,468 Sampo A shares representing 1.15 per cent of the total number of shares in Sampo plc.

Details of each transaction are included as an appendix of this announcement.

On behalf of Sampo plc,
Morgan Stanley Co. International plc

For further information, please contact:

Mirko Hurmerinta
Interim Head of Investor Relations
tel. +358 10 516 0032

Distribution:
Nasdaq Helsinki
Nasdaq Stockholm
Nasdaq Copenhagen
London Stock Exchange
FIN-FSA
The principal media
www.sampo.com

Attachment

Allschwil, Switzerland, September 14, 2026

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its partner Asahi Kasei Therapeutics Corp. started a phase 2 clinical study in Japan with the antifungal Cresemba® (isavuconazole) for pediatric patients at risk of deep mycoses.

Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “We are very pleased with the start of the pediatric study for Cresemba by our partner Asahi Kasei Therapeutics Corp. Invasive fungal infections pose a critical threat for children suffering from hematologic malignancies or immunodeficiency disorders. Despite this high-risk setting, treatment options remain limited. Making Cresemba available to pediatric patients in Japan would represent a major advance in addressing this important medical need.”

The multicenter, open-label, non-controlled study is assessing the safety and pharmacokinetics of Cresemba in children at risk from deep mycoses.

Cresemba is already approved for the treatment of children in the US, Canada, Europe and China. In Japan, Cresemba is approved for the treatment of adults with severe fungal infections, but currently not for use in pediatric patients.

About Cresemba® (isavuconazole)

Cresemba, with the active ingredient isavuconazole, is an intravenous (i.v.) and oral azole antifungal. Cresemba is marketed in more than 70 countries. In Japan, orally and intravenously administered isavuconazole is approved for use in adults for the treatment of aspergillosis (invasive aspergillosis, chronic progressive pulmonary aspergillosis, simple pulmonary aspergilloma), mucormycosis, and cryptococcosis (pulmonary cryptococcosis and disseminated cryptococcosis). Isavuconazole is also approved in the European Union1, the United Kingdom2, the United States (US)3 and many additional countries, including in the Asia Pacific region.4

According to the latest available market data, total global in-market sales of Cresemba in the twelve-month period between April 2025 and March 2026 amounted to USD 782 million, a 27 percent growth year-on-year, making it the largest branded antifungal for invasive fungal infections worldwide.5

Deep mycoses

Deep mycoses like invasive aspergillosis (IA), invasive mucormycosis (IM) and invasive cryptococcosis are life-threatening fungal infections that spread beyond superficial sites into deep tissues, including lung, eyes, brain, bones, the bloodstream, and other sites or organs. They predominantly affect immunocompromised patients, including patients with hematologic malignancies (blood cancer), transplant patients, or patients with immunodeficiency disorders. These infections are associated with high morbidity and mortality, also in pediatric patients.6, 7, 8

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations
Basilea Pharmaceutica International Ltd, Allschwil
Hegenheimermattweg 167b
4123 Allschwil
Switzerland

Phone +41 61 606 1102
E-mail media_relations@basilea.com
investor_relations@basilea.com

This press release can be downloaded from www.basilea.com.

References

  1. European Public Assessment Report (EPAR) Cresemba: https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba [Accessed: September 13, 2026]
  2. Summary of Product Characteristics (SmPC) Cresemba: https://www.medicines.org.uk/emc/search?q=cresemba [Accessed: September 13, 2026]
  3. Full US prescribing information: https://www.astellas.us/docs/cresemba.pdf [Accessed: September 13, 2026]
  4. The registration status and approved indications may vary from country to country.
  5. IQVIA Analytics Link, March 2026. In-market sales reported as moving annual total (MAT) in US dollar.
  6. J. Cadena, G. R. Thompson 3rd, T. F. Patterson. Aspergillosis: Epidemiology, Diagnosis, and Treatment. Infectious Disease Clinics of North America 2021 (35), 415-434
  7. M. Slavin, S. van Hal, T. C. Sorrell et al. Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality. Clinical Microbiology and Infection 2015 (21), 490.e1-490.e10
  8. Z. D. Pana E. Roilides, A. Warris et al. Epidemiology of Invasive Fungal Disease in Children. Journal of the Pediatric Infectious Diseases Society 2017 (6), suppl. 1, S3-S11

Attachment

Dear shareholder,

Dear Madam, Dear Sir,

The board of directors invites the shareholders to attend the extraordinary general meeting to be held on Thursday 15 October 2026 at 11.00h at the company’s seat, Begijnenvest 113, 2000 Antwerp. The shareholders are welcome as of 10.00h to facilitate compliance with the admission formalities to the meeting.

Please find attached the convening notice.

All related documents are available online: General Meetings | Ackermans & van Haaren

Best regards

Ackermans & van Haaren

Attachment

Aktsiaselts Infortar acquired its own shares on the Nasdaq Tallinn Stock Exchange during the period of 7 September – 11 September 2026 as follows:

Date Aggregated volume (pcs) Weighted average price per day (EUR)
07.09.2026 216 57,6778
08.09.2026 222 58,1369
09.09.2026 225 60,0000
10.09.2026 227 60,0000
11.09.2026 230 60,0000

Aktsiaselts Infortar is acquiring its own shares based on the stock exchange announcement published on 20 April 2026. The share buyback programme is managed by SEB Pank AS, which will buy back shares on behalf of Aktsiaselts Infortar.

Summary data (daily volume and weighted average prices) will be disclosed no later than on the seventh trading day following the transaction and be made available to the Estonian Financial Supervision and Resolution Authority, via the Nasdaq Tallinn system, and on Aktsiaselts Infortar´s investor website.

Further detailed information on the transactions is attached.

Infortar operates in seven countries, the company’s main fields of activity are maritime transport, energy and real estate. Infortar owns a 68.83% shareholding in Tallink Grupp, a 100% share in Elenger Grupp and a versatile and modern real estate portfolio of approx. 141,000 m2. In addition to the three main areas of activity, Infortar also operates in construction and mineral resources, agriculture, and other areas. A total of 107 companies belong to the Infortar group, including 3 associates and 2 subsidiaries of associates. Infortar employs 6890 people.

Additional information:

Kadri Laanvee
Investor Relations Manager
Phone: +372 5156662
e-mail: kadri.laanvee@infortar.ee
www.infortar.ee/en/investor

Attachment

  • Secured a substantial order to supply gas compression systems for the Cloud Connector Pipeline project
  • Awarded a major order for a modular liquefaction solution supporting Plaquemines LNG facility expansion
  • Awards deepen long-standing strategic collaboration with Venture Global

HOUSTON and LONDON, Sept. 13, 2026 (GLOBE NEWSWIRE) — Baker Hughes (NASDAQ: BKR) and Venture Global LNG are expanding their long-standing collaboration to advance critical U.S. gas infrastructure. Reinforcing Baker Hughes’ connected capabilities across the natural gas value chain, the company will provide gas compression systems for the Cloud Connector Pipeline project in Louisiana, as well as a modular liquefaction solution including cold boxes to support the expansion of the Plaquemines LNG facility.

Together, the pipeline and liquefaction awards demonstrate the critical role of integrated natural gas infrastructure in expanding LNG supply and enhancing energy security for global markets. The substantial pipeline award, which includes 13 gas compression systems driven by Frame 5/2E gas turbines, represents one of the largest deployments for LNG feed gas transportation in the United States. This will enable reliable and efficient transportation of feed gas through the Cloud Connector Pipeline to Venture Global’s Plaquemines facility.

Under the major liquefaction award, Baker Hughes will provide four liquefaction blocks, comprising a total of eight liquefaction modules, to support additional LNG production capacity at Plaquemines LNG facility. The liquefaction blocks include Chart cold boxes.

“Baker Hughes has been a trusted partner across our LNG developments, both at our LNG facilities and across our pipeline infrastructure,” said Mike Sabel, CEO of Venture Global. “As we advance the expansion of Plaquemines LNG, this collaboration not only supports our expansion plans, but also helps ensure we deliver the reliable feed gas transportation necessary to realize our mission of supplying secure LNG to global markets.”

“U.S. natural gas is helping to deliver the energy continuity required for industries, communities, and economies to thrive, grow and innovate. Baker Hughes is proud to work alongside our partners at Venture Global as they expand Plaquemines LNG, providing the critical energy infrastructure needed to meet growing global long-term global energy demand,” said Lorenzo Simonelli, chairman and CEO of Baker Hughes.

The liquefaction solution provided by Baker Hughes for the Plaquemines expansion follows a similar scope recently awarded for the CP2 project. Each liquefaction block is based on two electric-motor driven, single mixed-refrigerant (SMR) liquefaction modules and associated compression trains featuring Baker Hughes’ advanced centrifugal compressor technology, as well as cold boxes, air coolers and integrated control systems.

The Cloud Connector award is the second order of Frame 5/2E gas turbine-driven centrifugal compressor packages for Venture Global’s feed gas pipeline, expanding the fleet to 23 Frame 5/2E-driven gas compression systems for the Plaquemines LNG facility. The award further strengthens Baker Hughes’ strategic relationship with Venture Global, supporting more than 100 MTPA of existing and planned LNG production capacity, and reinforces Baker Hughes’ role as a leading industrialized energy provider across the natural gas value chain.

About Baker Hughes
Baker Hughes (NASDAQ: BKR) is an energy technology company that provides solutions to energy and industrial customers worldwide. Built on a century of experience and conducting business in over 120 countries, our innovative technologies and services are taking energy forward – making it safer, cleaner and more efficient for people and the planet. Visit us at bakerhughes.com.

For more information, please contact:

Media Relations

Adrienne M. Lynch
+1 713-906-8407
adrienne.lynch@bakerhughes.com

Investor Relations

Chase Mulvehill
+1 346-297-2561
investor.relations@bakerhughes.com

Agreement brings delayed and real-time OTC Link pricing to CITIC Securities Brokerage (HK) Limited’s Hong Kong clients through its trading platforms

NEW YORK, Sept. 13, 2026 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced a market data licensing agreement with CITIC Securities Brokerage (HK) Limited, a subsidiary of CITIC Securities International, the international arm of CITIC Securities.

Under the agreement, CITIC Securities Brokerage (HK) Limited will distribute OTC Markets pricing data to clients through its browser-based trading platform and mobile application. Delayed Level 1 quote data from OTC Link ATS, OTC Markets’ primary trading venue for US OTC equity securities, will be available on a 15-minute delayed basis from 6:00 a.m. to 5:00 p.m. Eastern time as a baseline offering to CITIC Securities Brokerage (HK)’s broader client base. Real-time Level 1 data will be available to premium subscribers, giving those clients direct visibility into live U.S. quote and trade activity.

The agreement extends OTC Markets pricing data to CITIC Securities Brokerage (HK) Limited’s retail client base across Hong Kong, connecting investors with data on more than 12,000 securities quoted across OTC Markets’ OTCQX, OTCQB, OTCID and Pink Limited markets, including international companies from Euronext, LSE, TSE, ASX and other exchanges that are cross-traded in the U.S.

“Investors in Hong Kong are asking for more visibility into their U.S.-traded interests,” said Matt Fuchs, EVP, Head of Market Data at OTC Markets Group. “This agreement gives CITIC Securities Brokerage (HK)’s clients access to key quote data on more than 12K global names traded in USD.”

“Access to reliable U.S. market data is part of how we serve clients who invest globally,” said Alan Fan, Chief Operating Officer of CITIC Securities Brokerage (HK) Limited. “This agreement strengthens that offering across our key trading platforms.”

The agreement reflects the growing demand for OTC Markets’ data capabilities in the Asia-Pacific region. In May, JP Chan was appointed Senior Vice President and Regional Head, Asia-Pacific, to lead the company’s growth across the region from Hong Kong.

International companies represent more than 90% of total dollar volume traded on OTC Markets, and demand for that data among investors outside the U.S. continues to grow.

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™ Basic Market, and Pink Limited™ Market.

Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.

OTC Link ATS, OTC Link ECN, OTC Link NQB, and MOON ATS® are each an SEC-regulated ATS, operated by OTC Link LLC, a FINRA and SEC-registered broker-dealer, member SIPC.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

About CITIC Securities Brokerage (HK) Limited

CITIC Securities Brokerage (HK) Limited is the Hong Kong wealth management platform of CITIC Securities, a leading Chinese investment bank with top-tier asset management scale. It primarily provides diversified, multi-market asset allocation solutions to high-net-worth individuals and corporate clients, with products and services covering multiple asset classes including funds, trusts, bonds, structured investment products, securities and futures.

Media Contact:

OTC Markets Group Inc.
Phone: (212) 896-4428
Email: media@otcmarkets.com

The Board of Directors of Kvika banki has appointed Jón Birgir Jónsson as Chief Executive Officer of Kvika banki. Jón Birgir will assume his new role on 1 December 2026, succeeding Ármann Þorvaldsson, who announced earlier this year his intention to step down as CEO.

Jón Birgir brings extensive experience from international financial markets, having spent most of his career in London and New York with two leading global asset management firms.

From 2013 to 2025, Jón Birgir was with Neuberger Berman in London, where he was a Partner and held a senior management role. He joined the firm to strengthen its global fixed income capabilities and subsequently took on broader responsibilities, including the management of relationships with professional and institutional investors. Prior to joining Neuberger Berman, he worked at J.P. Morgan Asset Management from 1998, in both New York and London, as a portfolio manager specialising in fixed income and global interest rate markets.

Jón Birgir holds a bachelor’s degree in mathematics from the University of Iceland and a graduate degree in financial engineering from New York University. While having spent much of his professional career abroad, he has maintained strong ties with the Icelandic business community, including through his service on the Board of the British-Icelandic Chamber of Commerce.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.